KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
MARKET OUTLOOK Following approval by the FDA in 2015, AbbVie’s Humira (adalimumab) became (and remains) the only approved therapy for the treatment of hidradenitis suppurativa. Humira is…
Overactive bladder is a common condition that manifests as a complex set of symptoms in the lower urinary tract and affects both men and women. It is characterized by sudden urges to urinate and…
Hypertriglyceridemia is characterized by elevated triglyceride (TG) levels. In addition to lifestyle changes, current treatment focuses on improving patients’ TG levels with the aim to reduce the…
Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth in 2020. Amgen / Novartis…
Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth in 2020. Amgen / Novartis…
With over a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and many more in the pipeline, the treatment journey for U.S. MS patients…
Despite heart failure with preserved ejection fraction (HFpEF) accounting for approximately half of all chronic heart failure (CHF) cases, and despite our improved understanding of the…
Osteoarthritic (OA) pain is the second-largest segment of the chronic pain therapy market and is expected to grow, driven by an aging population and the increasing prevalence of obesity. Yet a…
Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g.,…
Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread, with approved drugs available only for the…
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9…
Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well-established with a wealth of supporting evidence from clinical trials. ACE inhibitors or AIIRA/ARBs, beta…
Market Outlook Major depressive disorder (MDD) is a highly drug-treated condition that uses an array of drug classes including, but not limited to, serotonin reuptake inhibitors (SSRIs), selective…
In the United States a plethora of pharmacological treatments from an array of drug classes are available to patients with major depressive disorder (MDD), a highly drug-treated condition. Though…